Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters by Zakrzewska-Bode, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/20681
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Journal o f Hospital Infection (1995)  31, 1 89-193
Mupirocin resistance in coagulase-negative  
staphylococci, after topical prophylaxis for the 
reduction of colonization of central venous
catheters
A. Zakrzewska-Bode, H. L. Muytjens, K. D. Liem,* and
J* A. A. Hoogkamp-Korstanje
D ep a rtm en t o f  M ed ica l M icrobio logy a n d  * D ep a rtm en t o f  P a ed ia tr ic s , 
U n iversity  H o sp ita l N ijm egen , P .O . B o x  91 01 , 6500  H B  N ijm eg en , T h e
N eth erla n d s
A ccep ted  fo r  pub lica tion  7 J u ly  1995
S um m ary :  Topical mupirocin was routinely applied to insertion sites of 
central venous catheters (CVC) of neonates in a neonatal intensive care 
unit. After five years, mupirocin resistance was recorded in 42% of clinical 
isolates of coagulase-negative staphylococci (CNS). This decreased to 21% 
during a mupirocin-free interval of five months. We performed a prospective 
study on the significance of mupirocin use on the staphylococcal skin flora 
of 15 newly admitted neonates. During treatment, mupirocin-susceptible 
strains were replaced by highly resistant ones. After treatment, all but one 
neonate harboured at least one resistant strain; 29% of all strains were 
moderately resistant (mupirocin minimum inhibitory concentrations (MICs) 
16mg/L) and 55% were highly resistant (MICs >1024mg/L). One CVC 
(7%) became colonized with a resistant strain, One year after stopping routine 
mupirocin application the incidence of resistance had dropped to 13%; CVC 
colonization was recorded in 2*4%.
Keywords: Coagulase-negative staphylococci; mupirocin-resistance; central 
venous catheters; neonates.
Introduction
T h e prophylactic application of m upirocin to reduce colonization of central 
venous catheters (CVC) by coagulase-negative staphylococci (C N S ) was 
introduced in our neonatal intensive care unit (N IC U ) in 1988. T h is was 
associated w ith a decrease in the staphylococcal colonization rate of CVCs 
from 8*2% during 1987 to 2* 9% in 1991. T h e  isolation of m upirocin- 
resistant C N S from a catheter tip in January 1992, prom pted us to study  
the developm ent of resistance to m upirocin.
Methods
T he level of resistance to m upirocin am ong C N S from  clinical isolates of 
the N IC U  was determ ined during a m upirocin-free period of five m onths
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and then one m onth after réintroduction of the antibiotic. Controls were 
isolates from  36 patients hospitalized in an IC U  ward where mupirocin  
had never been used. Subsequently, the influence o f  m upirocin on C N S  
from skin flora was studied prospectively in  15, new ly  admitted, consecutive 
neonates (age 2-36  days), all w ith C VC s in  situ . M upirocin  ointm ent (2 % 
g/g) was applied once daily to the C VC  insertion site for 2 -24  days (mean 
seven days). One skin swab was taken from  each insertion site and the 
opposite site of the body before and during the insertion period (day 3-7) 
and after removal of the CVC (seven and 14 days after). Samples were 
cultured on 5% blood agar and m annitol-salt agar (48 h at 35°C, 5% C 0 2) 
and in Iso-sensitest broth, w hich was subcultured  after overnight incubation  
at 35°C on to blood agar and m annitol-salt agar. A ll CVCs were cultured 
after removal according to the m ethod of M aki et a l .x
Five colonies of G ram -positive, catalase-positive and coagulase-negative 
cocci (Staphaurex-negative) (M urex diagnostics, U trecht, T he Netherlands) 
were selected at random from each agar plate and identified by the API Staph 
system . T he susceptib ility  to lysozym e and novob iocin  (5 |ig disc diffusion, 
cu t-off diameter 16 m m ) was determ ined. T h e  susceptib ility  to mupirocin  
(M IC , m g/L ) was determ ined in duplicate by m icrodilution  in Iso-sensitest 
broth w ith an inoculum  of 105 c fu /m L  from  an overnight culture. The 
breakpoint for susceptib ility  was <4 m g/L ; isolates w ith  m upirocin M ICs 
of 4—64 m g/L  were considered low -level resistant, and those with mupirocin  
M IC s of > 700m g/L  as h igh-level resistant, F ish er’s exact test and W il- 
coxon’s test were used for statistical analysis.
Results
M upirocin resistance was found in clinical isolates of five out of nine 
patients in the N IC U  during D ecem ber 1991. A t the end of a five-m onth  
m upirocin-free period (from  1 M ay 1992-1 O ctober 1992) the resistance 
rate was 21%, compared w ith 8% in patients in the m upirocin-free IC U  
w here m upirocin was never used (P  —0 *2 ).
R éintroduction of m upirocin into the N IC U  resulted in an in-vitro 
resistance rate of 42% am ong clinical isolates after one month (Novem ber  
1992), whereas the prevalence in the com parative IC U  was 5% (P<0-05) 
(Table I).
Skin cultures o f the 15 neonates adm itted from  1 October 1992-1 May 
1993 revealed 208 strains (eight strains o f M icrococcus  spp. and 200 strains 
of C N S ). T h e  strains of C N S  were identified as S . epiderm idis (82%), S .  
zvarneri (8%), £ .  cap itis  (4*5%), S .  h aem o ly ticu s  (3%), S . hom inis (1-5%) and 
S .  sa p ro p h y ticu s  (1%). T he susceptib ility  o f these C N S to m upirocin is 
show n in Table II. Initially seven patients had only susceptible strains, 
three had both susceptible and low -resistant strains and five harboured 
both susceptible and highly resistant strains. T h e number of resistant 
strains increased during treatment: on days 3—7, seven of 13 neonates had
Table I. Mupirocin resistance among clinical isolates of patients hospitalized in the neonatal 
intensive care unit ( N I C U )  during periods with (M-\~) and without ( M - )  mupirocin 
prophylaxis compared with that found among isolates o f patients in the IC U  where mupirocin
was never applied
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Periods Test
No. of patients with 
resistance (total no.
studied) %
N IC U M +  Since 1988 December 1991 5 (9)
M -  1 May 1992-1 Oct. 1992 September 1992 4 (19) 21
M +  1 Oct. 1992-1 Apr. 1993 March 1993 5 (12) 42
M -  Since 1 April 1993 March 1994 2 (15) 13
ICU M — Ongoing September 1992 3 (36) 8
M — Ongoing March 1993 2 (39) 5
Table II. Range of minimum inhibitory concentrations (M IC s) (mg/L) of mupirocin of 
coagulase-negative staphylococci ( C N S ) isolates cultured from the skin of each patient> before 
(day 0), during (day 3-7) and after (7 and 14 days) topical mupirocin application
M IC  (mg/L)
No. of strains
Before
75 (8)*
During
65 (33)
After
60 (35)
Patient
1 0*25 (0) 0*25 (0) 0*25-8 (0)
2 0*12-16 (0) 0*12->1024 (2) 16—> 1024 (4)
3 0-12-0*25 (0) 0*12->1024 (2) >1024 (5)
4 0*12-0*25 (0) >1024 (5) 0*5—>1024 (3)
5 0*12-16 (0) 8“ > 1024 (2) 16—>1024 (2)
6 0*06->1024 (1) >1024 (5) 0T2->1024 (2)
7 0*12-0*25 (0) 16(0) 16(0)
8 0-12-16 (0) 0*5->1024 (3) 16—>1024 (4)
9 0T2->1024 (2) 0*12->1024 (3) 0*12-> 1024 (3)
10 0*12 (0) 0*12->1024 (3) 16—>1024 (3)
11 0*12—>1024 (2) >1024 (5) >1024 (5)
12 0*06~>1024 (1) NE NE
13 0*12—>1024 (2) NE NE
14 0*06-0*12 (0) 0*06->1024 (3) NE
15 0*12 (0) 16 (0) 16—>1024 (4)
* T h e  number of resistant isolates among five colonies from one sample are shown in brackets. 
N E, not evaluable.
acquired high-level resistant strains; on days 7—14, 10 out of 12 neonates, 
still hospitalized, harboured highly resistant strains (Figure 1). T hree  
neonates were not evaluable (one died and two were transferred to another 
hospital). Strains of C N S isolated from  other body sites show ed the same 
patterns o f resistance. One of IS CVC tips (7-7%) was colonized  w ith  a 
highly resistant S .  epiderm idis; all other tips were sterile.
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Figure 1. Selection of mupirocin resistance. Changes in coagulase-negative staphylococci 
of skin flora over time. (■ ) , Susceptible; (Ü), low resistance; (Ü ), high resistance.
A fter stopping prophylactic m upirocin  application, w e continued re­
cording m upirocin susceptib ility  in C N S  from  skin sw abs and CVCs taken 
from  N IC U  patients. After one year the level of resistance had fallen to 
13% and the precentage of colonized C VC s appeared to be 2*4%,
D iscussion
Our results clearly show  that the routine use o f m upirocin in a N IC U  can 
lead to the selection of resistant strains in skin flora. T h e  prevalence of 
resistant strains decreased after stopping the routine application of m u­
pirocin, but it was still at a high level after five m onths. Surprisingly, we 
found 5—8% resistance in an IC U  ward never using m upirocin . T he reason 
for this is unexplained, but it m ight have resulted from  cross-infection  
from the N IC U  or because o f the use o f m upirocin for m ethicillin-resistant 
S ta p h y lo co ccu s  aureus ( M R S A )  prophylaxis in  referring hospitals. However, 
we also found a m upirocin resistance rate of 10% in C N S  in the skin flora 
of neonates on adm ission to the N IC U  suggesting an unusually high level 
of naturally occurring resistance in our local population. T h e  slow decline 
in resistance after stopping m upirocin prophylaxis suggests that resistant 
strains may colonize the hospital staff and environm ent for long periods. 
Persistence o f a m ulti-resistant S .  ep iderm id is  clone in a N IC U  for four 
years has been  described .3 In our study, highly resistant strains easily 
replaced susceptible ones in the flora during therapy, thus creating a 
reservoir in w hich  h igh-level resistant isolates predom inated. Furthermore 
we found that prophylaxis had little beneficial effect on patients, since 
the percentage o f cu lture-positive CVCs during the study period was 
com parable w ith that observed during the period w ithout mupirocin.
We conclude that topical m upirocin is not useful for the prophylactic
Mupirocin resistance after prophylactic use 193
treatment o f CVCs and leads to the em ergence o f h igh-level m upirocin- 
resistant isolates. If this resistance were to transfer to S .  aureus in vivo> as 
it can in v itro *  it would make m upirocin unsuitable for treating M R SA  
carriers.
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